Jefferies upgraded Chemed’s rating from hold to buy and raised its price target from $520 to $620, implying roughly 22% upside from Monday’s close. The move followed quarterly results that beat analyst expectations, with shares up more than 2% in premarket trading. According to Jefferies analyst Brian Tanquilut, the group should regain stable, healthy earnings growth and recover a premium valuation after overcoming the Medicare hospice caps that constrained its client base and income potential in 2025. Over the past year, the stock has risen about 16%, compared with 23% for the S&P 500 healthcare sector, while the Roto-Rooter plumbing business is showing signs of stabilization. Three of the five analysts covering Chemed rate it buy or strong buy, while two rate it hold, according to LSEG data.
Source: Read the original article
